Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
Legal status of psychedelic substances by country
This information is for educational purposes only and may not reflect the most current legal status. Always verify with official government sources.
Countries Covered
30
Countries with Legal Access
16
Medical Exceptions
28
Active Research
19
Oregon: legal (supervised, 2023), Colorado: decriminalized (2022), FDA Breakthrough Therapy designation
FDA Breakthrough Therapy for PTSD, NDA submitted 2023
Esketamine (Spravato) FDA-approved for TRD (2019)
No active policy changes
UDV and Santo Daime religious exemptions (Supreme Court 2006)
No exceptions
Section 56 exemptions for end-of-life, Special Access Programme since 2022
Special Access Programme
Off-label use for depression widespread
Section 56 exemptions available
Section 56 exemptions; ayahuasca retreats in legal gray area
Legal, ibogaine clinics operate openly
Not explicitly illegal, gray area
Research only
Medical use approved, off-label depression treatment growing
Legal for religious use since 2010 (CONAD resolution)
Ibogaine clinics operate; not explicitly prohibited
Traditional/indigenous use tolerated; Mazatec ceremonies in Oaxaca
No exceptions
Medical use, growing off-label depression treatment
Ceremonial use tolerated
Legal; major destination for ibogaine treatment centers
Not explicitly prohibited; mushrooms grow naturally
Protected as indigenous cultural heritage; retreat industry
Medical use approved
Legal β not in the Dangerous Drugs Act. Retreat centers operate openly
No exceptions
Medical use only
Traditional use in Andean ceremonies tolerated
Declared cultural patrimony (2008); major ayahuasca retreat destination
Not regulated
Not explicitly prohibited; retreat centers operate
Retreat centers operate in legal gray area
Treatment centers operate openly